Abstract
The neuropeptide nociceptin/orphanin FQ (N/OFQ) can be released by stressors and is associated with disorders of emotion regulation and reward processing. N/OFQ and its receptor, NOP, are enriched in dopaminergic pathways, and intra-ventricular agonist delivery decreases dopamine levels in the dorsal striatum, nucleus accumbens (NAc), and ventral tegmental area (VTA). We used whole-cell electrophysiology in acute rat midbrain slices to investigate synaptic actions of N/OFQ. N/OFQ was primarily inhibitory, causing outward currents in both immunocytochemically identified dopaminergic (tyrosine hydroxylase positive (TH(+))) and non-dopaminergic (TH(–)) VTA neurons; effect at 1 μm: 20 ± 4 pA. Surprisingly, this effect was mediated by augmentation of postsynaptic GABAAR currents, unlike the substantia nigra pars compacta (SNc), where the N/OFQ-induced outward currents were K+ channel dependent. A smaller population, 17% of all VTA neurons, responded to low concentrations of N/OFQ with inward currents (10 nm: −11 ± 2 pA). Following 100 nm N/OFQ, the response to a second N/OFQ application was markedly diminished in VTA neurons (14 ± 10% of first response) but not in SNc neurons (90 ± 20% of first response). N/OFQ generated outward currents in medial prefrontal cortex (mPFC)-projecting VTA neurons, but inward currents in a subset of posterior anterior cingulate cortex (pACC)-projecting VTA neurons. While N/OFQ inhibited NAc-projecting VTA cell bodies, it had little effect on electrically or optogenetically evoked terminal dopamine release in the NAc measured ex vivo with fast scan cyclic voltammetry (FSCV). These results extend our understanding of the N/OFQ system in brainstem circuits implicated in many neurobehavioral disorders.
Significance Statement
The neuropeptide nociceptin/orphanin FQ (N/OFQ) and its receptor (NOP) are engaged under conditions of stress and are associated with reward processing disorders. Both peptide and receptor are highly enriched in ventral tegmental area (VTA) pathways underlying motivation and reward. Using whole-cell electrophysiology in rat midbrain slices we found: (1) NOPs are functional on both dopaminergic and non-dopaminergic VTA neurons; (2) N/OFQ differentially regulates VTA neurons based on neuroanatomical projection target; and (3) repeated application of N/OFQ produces evidence of receptor desensitization in VTA but not SNc neurons. These results reveal candidate mechanisms by which the NOP system regulates motivation and emotion.
Introduction
Nociceptin/orphanin FQ (N/OFQ) and its receptor (NOP) make up a neuropeptide signaling system de-orphaned in 1995 (Meunier et al., 1995; Reinscheid et al., 1995) that is engaged under conditions of stress (Ciccocioppo et al., 2000; Devine et al., 2001; Nicholson et al., 2002; Fernandez et al., 2004; Leggett et al., 2006, 2007; Green et al., 2007; Green and Devine, 2009; Nativio et al., 2012). The NOP is a G-protein coupled seven-transmembrane domain receptor that canonically signals through Gi/o proteins, postsynaptically activating G-protein-coupled inward-rectifying potassium channels (GIRKs), or presynaptically reducing probability of neurotransmitter release via inhibition of N-type calcium channels (Knoflach et al., 1996; Vaughan and Christie, 1996; Hawes et al., 2000; New and Wong, 2002). While amino acid sequence homology has led some to categorize the NOP as an opioid receptor (Bunzow et al., 1994; Mollereau et al., 1994; Wang et al., 1994; Meunier et al., 1995), NOP activation is not blocked by naloxone, a non-selective opioid receptor antagonist that was originally used to classify responses as opioid receptor mediated, blocking activation at μ, δ, and κ opioid receptors (MOPs, DOPs, and KOPs, respectively; Reinscheid et al., 1995, 1996; Gintzler et al., 1997; Mogil and Pasternak, 2001). Furthermore, the known endogenous opioid peptides (dynorphins, enkephalins, and endorphins) do not bind to the NOP, and N/OFQ does not bind to the MOP, DOP, or KOP (Meng et al., 1996; Sim et al., 1996; Ma et al., 1997). Because of the extensive amino acid sequence homology and these distinct pharmacological properties, N/OFQ and the NOP are most appropriately subclassified as non-classical members of the opioid family (Cox et al., 2015; Toll et al., 2016).
N/OFQ and the NOP are highly enriched in the ventral tegmental area (VTA), dorsal striatum, nucleus accumbens (NAc), medial prefrontal cortex (mPFC), and central nucleus of the amygdala (Neal et al., 1999; Berthele et al., 2003; Parker et al., 2019). The VTA is the major source of dopamine to limbic forebrain regions and plays a key role in brain networks that coordinate motivation and learned appetitive behaviors (Fields et al., 2007). Activity of VTA dopamine neurons is associated with salience and reward prediction, while destruction of these neurons results in motivational deficits (Ungerstedt, 1971; Wise, 2005; Fields et al., 2007; Tsai et al., 2009; Witten et al., 2011; Kim et al., 2012; Morales and Margolis, 2017; Mohebi et al., 2019). Intracerebroventricular (ICV) injections of N/OFQ produce a decrease in extracellular dopamine in the dorsal striatum and NAc, and some midbrain putative dopamine cell bodies are inhibited by NOP activation (Murphy et al., 1996; Murphy and Maidment, 1999; Di Giannuario and Pieretti, 2000; Lutfy et al., 2001; Zheng et al., 2002; Vazquez-DeRose et al., 2013).
Dysregulation of the N/OFQ system has been associated with disorders of motivated responding (Civelli and Zhou, 2008), and the N/OFQ system has been investigated as a novel therapeutic target for major depressive disorder and alcohol use disorder (Witkin et al., 2019); however, understanding the involvement of the N/OFQ system in these behaviors remains a challenge. In fact, in some cases, activation and blockade of NOPs paradoxically produce the same behavioral outcomes, for example with alcohol consumption (Kuzmin et al., 2007; Ciccocioppo et al., 2014; Rorick-Kehn et al., 2016) and anxiety-related behaviors (Jenck et al., 1997; Dautzenberg et al., 2001; Gavioli et al., 2002; Fernandez et al., 2004; Kamei et al., 2004; Vitale et al., 2006; Green et al., 2007; Varty et al., 2008). Such observations may be explained by off-target effects of N/OFQ, activation of N/OFQ sensitive neural circuits that compete for behavioral control, or receptor desensitization.
Here, we investigated the basic physiology of N/OFQ responses in VTA neurons to better characterize how N/OFQ contributes to motivation and reward processing. To confirm that our physiological responses to N/OFQ were because of NOP activation we used the selective NOP antagonist BTRX-246040 (Toledo et al., 2014) to block N/OFQ responses. We observed similar N/OFQ effects on both dopamine and non-dopamine VTA neurons. Importantly, we found that responses to N/OFQ differ between VTA and substantia nigra pars compacta (SNc) neurons in mechanism of inhibition and functional desensitization measures. Furthermore, we found that for VTA neurons, N/OFQ responses vary by the projection target. For example, N/OFQ induced small inward currents preferentially in VTA neurons that project to the posterior anterior cingulate cortex (pACC). In addition, although NAc-projecting cell bodies were inhibited by NOP activation, N/OFQ induced minimal inhibition of dopamine release at terminals in the NAc. Together, these observations indicate that NOP actions vary not only by brain region and neuron subpopulation but also by structural localization within a neuron.
Materials and Methods
Electrophysiology
Most experiments were completed in tissue from male Sprague Dawley rats, post-natal day 22–36, except mechanism experiments which were completed in tissue from adult rats (>200 g). Rats were anesthetized with isoflurane, and brains were removed. The brains were submerged in Ringer’s solution containing the following: 119 mm NaCl, 2.5 mm KCl, 1.3 mm MgSO4, 1.0 mm NaH2PO4, 2.5 mm CaCl2, 26.2 mm NaHCO3, and 11 mm glucose saturated with 95% O2–5% CO2 and horizontal brain slices (150 µm thick) containing the VTA were prepared using a Vibratome (Leica Instruments). Slices were then allowed to recover at 35°C for at least 1 h before recordings were initiated. The same Ringer’s solution was used for cutting, recovery, and recording.
Individual slices were visualized under an Olympus BX50WI microscope (Olympus Life Science Solutions) with differential interference contrast optics and near infrared illumination, using an Andor xIon+ camera, and Andor Solis imaging software (Andor Technology Ltd), or under a Zeiss Axio Examiner.D1 with differential interference contrast optics, near infrared illumination, and Dodt contrast, using a monochrome Axiocam 506 (Zeiss International). Whole-cell patch-clamp recordings were made at 33°C using 2.5–4 MΩ pipettes containing the following: 123 mm K-gluconate, 10 mm HEPES, 0.2 mm EGTA, 8 mm NaCl, 2 mm MgATP, and 0.3 mm Na3GTP, pH 7.2, osmolarity adjusted to 275 mOsm. Biocytin (0.1%) was added to the internal solution for post hoc identification.
Recordings were made using an Axopatch 1-D (Molecular Devices), filtered at 2 kHz, and collected at 20 kHz using IGOR Pro (Wavemetrics) or an IPA amplifier with SutterPatch software (Sutter Instrument) filtered at 1 kHz and collected at 10 kHz. Liquid junction potentials were not corrected during recordings. Hyperpolarization-activated cation currents (Ih) were recorded by voltage clamping cells and stepping from −60 to −40, −50, −70, −80, −90, −100, −110, and −120 mV. The Ih magnitude was measured as the difference between the initial response to the voltage step after the capacitive peak and the final current response.
Pharmacology experiments were completed in voltage-clamp mode (V = −60 mV) to measure changes in membrane current. Series resistance was monitored online by measuring the peak of the capacitance transient in response to a −4 mV voltage step applied at the onset of each sweep. Input resistance was measured using the steady state response to the same voltage step. Upon breaking into the cell, at least 10 min was allowed for the cell to stabilize and for the pipette internal solution to dialyze into the cell. Drugs were applied via bath perfusion at a flow rate of 2 mL/min or pressure ejection using a SmartSquirt micro-perfusion system (AutoMate Scientific) coupled to a 250-µm inner diameter tubing outlet positioned nearby the recorded cell (within ∼200 µm). N/OFQ (1 nm to 10 μm) was bath applied (5–7 min) or pressure injected (2 min) only after a 5-min stable baseline was achieved. Responses were similar to the two forms of N/OFQ application at the same concentrations. For instance, at 100 nm, bath application 10.1 ± 1.5 pA, n = 21; pressure ejection 9.8 ± 2.1 pA, n = 12. As there was no statistical difference in the mean amplitude of response for bath application and pressure injection, the results were combined for the analysis. Any cell that showed drift or did not maintain a consistent baseline current for the full 5-min period was removed from the analysis. All experiments where repeated N/OFQ applications are reported, such as the desensitization experiments, were completed with bath application. To test that observed N/OFQ-mediated effects were specific to NOP, the selective NOP antagonist BTRX-246040 (100 nm) was applied for 10 min before N/OFQ.
For iontophoresis experiments, the holding current was set to −50 mV to increase the driving potential for Cl–. GABA (100 mm, pH adjusted to 4.9 with 37% HCl) was prepared daily and the GABA-containing pipette was positioned ∼50 µm away from the recorded neuron. Negative retention current (approximately −35 nA) was applied to the GABA pipette, interrupted by positive ejection current pulses (100 ms) once every 30 s, with the intensity adjusted so that the response amplitude was in the range of 100–300 pA.
Stock solutions of drugs were made in advance, stored at −20°C, and diluted into artificial CSF (aCSF) immediately before application. N/OFQ was obtained from Tocris and diluted to a 100 μm stock solution in ddH2O. Stock BTRX-246040 was obtained from BlackThorn Therapeutics and dissolved in dimethylsulfoxide (10 mm).
Retrograde tracer injections
Male Sprague Dawley rats, 21–100 d old, were anesthetized with isoflurane. A glass pipette (30- to 50-µm tip) connected to a Nanoject II/Nanoliter 2000 microinjector (Drummond Scientific Co) was stereotaxically placed in the mPFC [from bregma: anteroposterior (AP), +2.6 mm; mediolateral (ML), ±0.8 mm; ventral (DV), −4.0 mm from skull surface], the pACC (AP, 1.6 mm; ML, ±0.6 mm; V, −3.5 mm), or the NAc (AP, +1.5 mm; ML, ±0.8 mm; V, −6.7 mm). Neuro-DiI (7% in ethanol; Biotium) was slowly injected, 50.6 nL per side. Animals were allowed to recover for 5–7 d, while the retrograde tracer transported back to the cell bodies. On the day of recording, the experimenter was blind to the location of retrograde tracer injection (mPFC, pACC, or NAc), and slices were prepared as above. Projection neurons were chosen by selecting cells observed as labeled using epifluorescent illumination. All injection sites were histologically confirmed by a third party blind to the electrophysiology results to avoid bias. N/OFQ responses were analyzed before unblinding. Animals with improper injection placements or significant diffusion outside of the target region were rejected.
Immunohistochemistry
Slices were preblocked for 2 h at room temperature in PBS with 0.2% BSA and 5% normal goat serum, then incubated at 4°C with a rabbit anti-TH polyclonal antibody (1:100; EMD Millipore, RRID: AB_390204). Slices were then washed thoroughly in PBS with 0.2% BSA before being agitated overnight at 4°C with Cy5 anti-rabbit secondary antibody (1:100; Jackson ImmunoResearch, RRID: AB_2534032) and FITC streptavidin (6.5 µL/ml). Sections were rinsed and mounted on slides using Bio-Rad Fluoroguard Antifade Reagent mounting media and visualized with an Axioskop FS2 Plus microscope with an Axiocam MRm running Neurolucida (MBF Biosciences). Neurons were only considered TH(−) if there was no colocalization of biocytin with TH signal and the biocytin soma was in the same focal plane as other TH(+) cell bodies. Primary antibodies were obtained from Millipore Bioscience Research Reagents or Millipore, secondary antibodies were obtained from Jackson ImmunoResearch, and all other reagents were obtained from Sigma Chemical.
Fast scan cyclic voltammetry (FSCV)
Male Sprague Dawley rats, 21–26 d old, or Th::Cre transgenic rats (Witten et al., 2011), 46–51 d old at the time of virus injection, were used in these studies. Th::Cre rats were injected with the Cre-dependent ChR2-expressing virus (AAV2-Ef1a-DIO-hChR2(H134R)-mCherry, titer 5.1 × 1012 viral particles/mL, UPenn viral core) bilaterally into the VTA 500 nL per side (AP, −5.3 mm; ML, ± 0.4 mm; DV, −8.2 mm from bregma). Five weeks later, coronal slices (400 µm) containing the NAc were prepared for voltammetry measurements. The use of Cre dependent ChR2 expression allowed selective optical control of VTA dopamine terminals in the NAc.
Extracellular dopamine release was achieved using either electrical (in wild-type Sprague Dawley rats) or 470-nm light (in Th::Cre rats) stimulation. Stimulation parameters were the same for both electrical and optical stimulation (10 Hz, two pulses, 4 ms). Electrochemical recordings were made using carbon fiber electrodes fabricated from T-650 carbon fiber (7 µm diameter, gift from Leslie Sombers, NCSU) that was aspirated into a borosilicate glass capillary (0.6 × 0.4 mm or 1.0 × 0.5 mm in diameter, King Precision Glass Inc.) and pulled using a PE-22 puller (Narishige). Carbon fiber electrodes were positioned 80 µm into the tissue either between the bipolar tips of the stimulating electrode or directly in front of an optical fiber connected to an LED emitting 470 nm light (7–10 mW). The potential of the carbon fiber electrode was held at −0.4 V relative to the Ag/AgCl reference electrode. A triangle wave form was applied to the carbon fiber driving the potential from −0.4 to +1.3 V and back to −0.4 V at a rate of 400 V/s, at 60 Hz for conditioning and 10 Hz for data collection. Data were collected with a WaveNeuro FSCV potentiostat (Pine Research) using HDCV acquisition software package (freely available through UNC Department of Chemistry). HDCV Acquisition Software was used to output the electrochemical waveform and for signal processing (background subtraction, signal averaging, and digital filtering; four-pole Bessel filter, 2.5 kHz). Dopamine release was stimulated at 2 min intervals for electrical stimulation and 3 min intervals for optical stimulation. The difference in stimulation intervals was to decrease rundown of the dopamine release signal that can be particularly strong in optical experiments as reported in (Bass et al., 2013; O'Neill et al., 2017). Mean background currents from 1 s of data before stimulation were removed by subtraction of cyclic voltammograms for each trial.
Data analysis
For electrophysiology, effects of N/OFQ were statistically evaluated in each neuron by binning data into 30 s data points and comparing the last eight binned predrug points to the last eight binned points during drug application using Student’s unpaired t test. To evaluate the output of this analysis approach, we performed a subsequent sliding window analysis on this classified data from TH(+) neurons that were tested with 10 nm N/OFQ (Extended Data Fig. 1-1). The results of this analysis are consistent with this classification scheme identifying drug responses and a lack of contamination by drift in individual recordings. The summary effect sizes reported here are the differences between the mean of this baseline 4 min window and the mean of the Iholding during the last 4 min of drug application. For within cell comparisons of N/OFQ responses, responses were compared with a Student’s paired t test; p < 0.05 was required for significance in all analyses. Differences between neuron populations were tested using two-tailed permutation analyses unless otherwise indicated. Violin plots were constructed by calculating the kernel density estimate, made using a Scott estimator for the kernel bandwidth estimation. The kernel size was determined by multiplying the Scott bandwidth factor by the SD of the data within each bin. Each individual violin plot was normalized to have an equal area under the curve. Time course figures are averages of the binned current traces for all cells time locked to the start of drug application. EC50 was estimated by fitting the concentration response data with the Hill equation. Results are presented as mean and SEM. Custom code created for analyses here are publicly available at https://osf.io/c8gu7/?view_only=24595243ef6d44d5974442b23dda0b1d.
Results
N/OFQ effects on holding current in VTA dopamine and non-dopamine neurons
To test the postsynaptic responses of VTA neurons to N/OFQ, we made ex vivo whole-cell voltage-clamp recordings (Vm = −60 mV). N/OFQ application changed the holding current in 70% (60/86) of neurons tested in the VTA (10 nm; 86 neurons from 59 rats; Fig. 1A,B). The majority of responses were relatively small outward currents (73% of responsive neurons, 44/60; 51% of all neurons tested, 44/86; mean response magnitude = 15 ± 2 pA; Fig. 1D; examples of small responses provided in Extended Data Fig. 1-2A-C). In many cases, the holding current returned to baseline during N/OFQ washout, as in Figure 1A; however, in some cases, we observed only partial recovery. Using post hoc immunocytochemistry, we analyzed TH content in each histologically recovered neuron and found that N/OFQ inhibited both confirmed dopamine and non-dopamine neurons in similar proportions [of 44 inhibited neurons from 38 rats, 26 neurons from 23 rats were identified: TH(+): 12/26; TH(–): 14/26]. The magnitudes of responses were also similar between confirmed dopamine and non-dopamine neurons [TH(+): 12 ± 2 pA (n = 12); TH(–): 9 ± 2 pA (n = 14); p = 0.3 two-tailed permutation test; Fig. 1C]. The EC50 for these outward currents is in the nM range (8 ± 6 nm; Fig. 1E).
Extended Data Figure 1-1
To evaluate our within cell statistical comparisons to identify “responsive” versus “non-responsive” neurons, in particular to test the possibility that drift might contribute to some of our identified drug effects, we conducted a sliding window analysis on a subset of our drug responses (all TH-positive neurons tested with bath application of 10 nm N/OFQ). Further, any increase in statistically significant sliding windows during drug washout compared to the static baseline would suggest underlying Iholding drift. We compared all 4-min windows from predrug application through drug washout to a fixed “baseline” window (the 4 min preceding the onset of the drug). To create the windows, Iholding of each recording was binned into 30-sec intervals and assigned a bin number (1, 2, 3 Ö n). The baseline eight-bin (4-min) window was compared with the target 4-min window by way of a Student’s unpaired t test. The p value and significance of the comparison were then corrected using the Bonferroni method for multiple comparisons. The alignment of the sliding window was then increased by a single bin and the comparison repeated, resulting in an array that represents all significant 4-min intervals for each drug effect. The resulting arrays were plotted as a histogram representing, at the initial bin time of the sliding window, the proportion of recordings in which this calculation was significantly different from the fixed baseline target window (A). In the neurons previously classified as responsive by a single baseline compared to “drug” window comparison, the rising left edge of the histogram begins to plateau around the 4th minute of drug application, consistent with the plateau of the mean effects across all cells reported in Figure 1D. Further, consistent with washout reversal of N/OFQ effects in most but not all neurons, the proportion of significant bins falls off as soon as N/OFQ application was terminated. That both the rise and fall of the frequencies of significant windows are time locked to the drug application suggests the response classification scheme is reliable. In neurons previously classified as non-responsive only one neuron had any significant windows, with three sliding window locations where this analysis yielded p < 0.05, suggesting that there was not systematic drift in these non-responsive neurons. In addition, a scatter plot (B) indicates the maximum number of consecutive significant sliding windows for each cell analyzed, because a well-behaved change in Iholding in response to the drug application should be detected in consecutive sliding windows. This graph shows that 8/12 neurons that were classified as responsive have more consecutive sliding windows different from baseline than the maximum found in non-responsive neurons. This analysis was conducted using a custom script created in Python (available at https://osf.io/c8gu7/?view_only=24595243ef6d44d5974442b23dda0b1d). Download Figure 1-1, EPS file.
Extended Data Figure 1-2
These graphs show the whole-cell voltage-clamp recordings of the three smallest changes in holding current that were categorized as responses to 10 nm N/OFQ by statistical analysis for Figures 1B, 3C, outward, left; inward, right. Grey boxes indicate drug application. Blue boxes indicate baseline measurement interval, green boxes indicate drug effect measurement interval. Download Figure 1-2, EPS file.
To confirm responses were due to activation of the NOP, we tested whether these inhibitions were blocked by the selective NOP antagonist BTRX-246040. In neurons responding to N/OFQ with an outward current, BTRX-246040 (100 nm) was applied for 10 min and then N/OFQ was applied a second time in the presence of the antagonist. BTRX-246040 consistently blocked N/OFQ-induced outward currents (baseline 10 nm N/OFQ response: 14 ± 3 pA; N/OFQ response in BTRX-246040: −1 ± 2 pA; n = 15; 14 rats; paired t test: p = 0.0005; Fig. 2).
We also observed a subpopulation of neurons that responded to N/OFQ application with a small inward current, consistent with an excitatory effect (10 nm mean response = −16 ± 6 pA; Fig. 3A,B). Inward currents were observed in ∼25% (15/60) of the neurons that were responsive to N/OFQ (10 nm) and 17% of all 10 nm-tested VTA neurons (15/86; 15 neurons from 14 rats; Fig. 3C,D; examples of small responses provided in Extended Data Fig. 1-2D-F). Among five neurons responding to N/OFQ with an inward current and immunocytochemically identified, 40% (2/5) were TH(+) and 60% (3/5) were TH(–) (two-tailed permutation test: p = 0.6; Fig. 3E). These N/OFQ evoked excitatory responses were only observed at low concentrations (≤100 nm; Fig. 3D); at higher concentrations, only outward currents were observed (Figs. 1E, 3D). The neurons showing this excitatory response to N/OFQ were topographically intermixed with VTA neurons that responded to N/OFQ with an outward current (Fig. 3F).
Concentration-dependent desensitization of NOPs
Given the inconsistencies in the reports of behavioral effects of NOP agonists and antagonists, we tested whether N/OFQ causes rapid NOP desensitization at moderate doses. We observed a concentration-dependent diminished response to a second application of N/OFQ when the first application of N/OFQ was ≥ 100 nm (n = 12 neurons from 12 rats; paired t test p = 0.00003; Fig. 4A,B). This is consistent with NOP desensitization, and observed in both TH(+) and TH(–) neurons (Fig. 4B). In contrast, following administration of 10 nm N/OFQ, no significant difference in response was observed between the second and first applications (n = 10 neurons from 8 rats; paired t test p = 0.13; Fig. 4C,D). Therefore, desensitization occurs at moderate N/OFQ concentrations in the VTA.
N/OFQ inhibits VTA neurons and SNc neurons via different cellular mechanisms
We investigated the mechanism underlying the outward currents produced by N/OFQ in VTA neurons. These experiments were completed in adult animals to ensure we measured the mature mechanisms of N/OFQ actions. The most common mechanism by which Gi/o coupled receptors, including the NOP, generate somatodendritic electrophysiological inhibition is by activation of GIRKs. First, we tested whether the K+ channel blocker BaCl2 (100 µm) prevented N/OFQ-induced outward currents. Surprisingly, BaCl2 did not prevent the outward currents induced by N/OFQ at either 100 nm (Fig. 5A) or 10 nm [Fig. 5B; one tailed permutation analysis comparing all 10 nm N/OFQ VTA observations from p22–p36 animals in Fig. 1 (n = 86) to 10 nm N/OFQ observations in the presence of 100 µm BaCl2 (n = 7), p = 0.2; each recording with a outward current response >1.5 pA is shown in Extended Data Fig. 5–1A-C]. We next tested whether a cocktail of synaptic blockers including the Na+ channel blocker tetrotodoxin (TTX; 500 nm), the AMPA receptor (AMPAR) blocker 6,7-dinitroquinoxaline-2,3(1H,4H)-dione (DNQX; 10 μm), and the GABAAR antagonist bicuculline (10 μm) would alter N/OFQ responses. Interestingly, while this cocktail did not significantly change the mean of VTA neuron N/OFQ responses [Fig. 5C; the one recording with a outward current response >1.5 pA is shown in Extended Data Fig. 5-1D; two-tailed permutation analysis comparing the means of all 10 nm N/OFQ VTA observations from p22–p36 animals in Fig. 1 (n = 86) to 10 nm N/OFQ observations in the synaptic blocker cocktail (n = 9), p = 0.16)], only one out of nine neurons responded to 10 nm N/OFQ with an outward current under these conditions (Extended Data Fig. 5-1D), raising the possibility of a difference in the proportion of neurons with this type of response in the inhibitor cocktail. The SD of the distribution of N/OFQ responses in the presence of the inhibitor cocktail was significantly reduced, also consistent with the possibility this treatment diminished N/OFQ responses (one tailed permutation analysis comparing the SDs of all 10 nm N/OFQ VTA observations from p22–p36 animals in Fig. 1; SD = 20.36 pA, variance = 414.53 pA, n = 86) to 10 nm N/OFQ observations in the synaptic blocker cocktail (SD = 6.27 pA, variance = 39.27 pA, n = 9), p = 0.03; 10 nm N/OFQ observations in BaCl2 (SD = 9.34 pA, variance = 87.27 pA, n = 9), p = 0.15]. Since the cocktail of synaptic blockers did not yield a significant change in the mean of the responses, this was most consistent with both outward and inward current responses being diminished. Focusing on the outward currents, if these blockers decreased the outward current responses to N/OFQ, the simplest possible mechanisms are via an inhibition of AMPAR signaling, via an increase in GABAAR signaling, or via a non-GIRK-dependent effect of a substance released by action potential activity in the slice. We previously found that in stressed animals, DOP activation in the VTA postsynaptically increases GABAAR signaling in VTA neurons (Margolis et al., 2011), and there is evidence for tonic GABAAR currents in VTA neurons (Darnieder et al., 2019). On the other hand, spontaneous glutamate release in the VTA seems insufficient to support generating an apparent outward current when glutamate release is inhibited (Koga and Momiyama, 2000; Margolis et al., 2005; Xiao et al., 2009). Therefore, we tested whether N/OFQ affects GABAAR signaling in the VTA and whether this might account for N/OFQ-induced changes in holding current. We iontophoretically applied GABA in the presence of GABABR blockade (CGP35348, 30 μm) to measure GABAAR responses and to bypass any potential presynaptic terminal effects. We not only found that 100 nm N/OFQ increased the amplitude of GABAAR responses (Fig. 5D,E), the effect on iontophoresed GABA currents was proportional to the change in holding current induced by N/OFQ (Fig. 5E), across both inward and outward currents induced by N/OFQ, making it likely that GABAAR signaling underlies both inward and outward currents induced by N/OFQ application to VTA neurons.
Extended Data Figure 5-1
These graphs show each of the whole-cell voltage-clamp recordings represented in the summary dot plots in Figure 5B,C where the 10 nm N/OFQ-induced change in holding current >1.5 pA. In control experiments, 55/86 neurons (64%) responded to 10 nm N/OFQ with a change in holding current >1.5 pA. In the case of BaCl2 experiments, 3/7 (43%) of the tested neurons responded with a change in holding current >1.5 pA (A–C). In one of these neurons, we tested the N/OFQ response twice, and the neuron responded with an outward current both times (top example). For experiments in which we tested for 10 nm N/OFQ responses in the presence of TTX, DNQX, and bicuculline, only 1/9 neurons (11%) responded with a change in holding current >1.5 pA (D). In this example, the change in holding current induced by the cocktail of blockers is apparent during minutes 0–3. Download Figure 5-1, EPS file.
That N/OFQ-induced outward currents are because of augmentations of GABAAR-mediated current rather than activation of a K+ current was particularly surprising because it was previously reported that N/OFQ activates a K+ channel in VTA neurons (Zheng et al., 2002). Zheng and colleagues also reported larger average outward currents compared with our dataset and did not observe desensitization with repeated applications of 300 nm N/OFQ, inconsistent with our findings here. As a positive control to test that 100 μm BaCl2 was sufficient to block K+-mediated effects in our preparation, and in an attempt to resolve these discrepancies, we completed additional recordings in the SNc, just lateral to the VTA (Fig. 5I). First, we tested whether repeated application of 100 nm N/OFQ to SNc neurons resulted in less desensitization than we observed in VTA neurons. In fact, the response to the second 100 nm N/OFQ application was not statistically different from the response to the first application in SNc neurons, in contrast to VTA neurons (Fig. 5F,G; two-tailed paired t test, p = 0.5, n = 5). Therefore, we used a within cell design to compare the N/OFQ response in control aCSF and in 100 µm BaCl2. Blocking K+ channels significantly reduced the magnitude of N/OFQ responses in SNc neurons (Fig. 5H; one-tailed paired t test, p = 0.003, n = 5). Together, these observations indicate that BaCl2 was fully capable of blocking GIRK-mediated N/OFQ effects in our recording conditions and suggest that the differences between our observations and those previously reported may be related to recording location (Fig. 5I).
N/OFQ effects on VTA neurons vary with projection target
As described above, we observed heterogeneity in responses of VTA neurons to N/OFQ. Given that other pharmacological responses of VTA neurons, including to KOP activation (Ford et al., 2006; Margolis et al., 2006), vary with projection target, we investigated whether the N/OFQ responses would be more consistent within subpopulations of VTA neurons that share a projection target. Accordingly, we recorded N/OFQ (10 nm) responses in VTA neurons that were retrogradely labeled by tracer injections into mPFC, pACC, or medial NAc (Fig. 6A,B). Recordings were conducted with the investigator blinded to the injection site.
The majority of mPFC-projecting VTA neurons, 67% (8/12), were significantly inhibited by N/OFQ, responding with an outward current (11 ± 3 pA; eight responsive neurons from six rats; Fig. 6D,E). No N/OFQ-induced inward currents were observed in mPFC-projecting neurons. Five mPFC-projecting neurons were recovered and processed for TH immunoreactivity (Fig. 6C,E); two were TH(+), and three were TH(–); all of these responded to N/OFQ with an outward current (Fig. 6E).
VTA projections to different cortical targets, including the pACC, arise from largely separate VTA neurons (Chandler et al., 2013). The pACC-projecting neurons are concentrated in different parts of the VTA, and fewer of them are dopaminergic compared with the projection to mPFC (Breton et al., 2019). Interestingly, 67% of the VTA neurons comprising this projection responded to N/OFQ with an inward current (4/6 inward current, −24 ± 12 pA, 1/6 outward current, from four rats; Fig. 6D,E). These N/OFQ excited, pACC-projecting VTA neurons included both TH(+) and TH(–) cells (Fig. 6E).
Half of NAc-projecting VTA neurons (7/14) responded to N/OFQ with outward currents (9 ± 1 pA, seven responsive neurons from seven rats; Fig. 6D,E). No inward currents were observed in this projection. Of the seven NAc-projecting neurons that responded to N/OFQ, two were confirmed TH(+) and three were TH(–) (Fig. 6E). Together, these data indicate that similar N/OFQ inhibitory effects occur in VTA neurons that project to mPFC and NAc, but these effects are opposed to those on VTA projections to pACC, many of which responded to N/OFQ with an inward current.
N/OFQ has minimal effect on terminal dopamine release in the NAc
ICV or intra-VTA N/OFQ decreases dopamine levels in the NAc (Murphy et al., 1996; Murphy and Maidment, 1999). Consistent with this result, we found that N/OFQ directly inhibits a subset of the NAc-projecting VTA dopamine somata. N/OFQ may also inhibit dopamine release in the NAc at the terminals; to test whether NOPs on dopamine terminals in the NAc also contribute to an N/OFQ-induced decrease in NAc dopamine levels, we used FSCV to detect changes in stimulated dopamine release in NAc slices (Fig. 7A). In tissue from control SD rats (nine rats), we stimulated dopamine release with a bipolar electrode. In a second set of animals, to limit stimulation to dopaminergic axons, we expressed ChR2 in Th::Cre rats and stimulated with 470-nm light pulses (nine rats). In these preparations, repeated electrical, and especially optical, stimulation can cause rundown in evoked dopamine release over time (Bass et al., 2013; O'Neill et al., 2017). To minimize this rundown as much as possible, we increased the intervals between light stimulations to 3 min. Where recordings were stable, effects of 10 nm N/OFQ, 100 nm N/OFQ, and 1 µm U69,593 were sequentially tested. At 10 nm N/OFQ, approximately the EC50 of the outward currents recorded at VTA somata, there was no change in the peak FSCV response to either electrically or light evoked dopamine release (electrically evoked dopamine release: 93 ± 4% of baseline, n = 9 slices from 9 rats: linear mixed effects model, z = −1.3, p = 0.2; optically evoked dopamine release: 94 ± 10% of baseline, n = 5 from 5 rats: linear mixed effects model, z = −0.5, p = 0.6; Fig. 7A,B). We detected a small but significant decrease in evoked dopamine release in response to 100 nm N/OFQ (electrically evoked dopamine release: 88 ± 7% of baseline, n = 11 from 9 rats: linear mixed effects model, z = −2.1, p = 0.04; optically evoked dopamine release: 74 ± 4% of baseline, n = 17 from 9 rats: linear mixed effects model, z = −7.2, p < 0.001; Fig. 7B). Consistent with previous studies (Bass et al., 2013; O'Neill et al., 2017), it is possible that this small decrease was driven, at least in part, by rundown of ChR2-driven dopamine release. As a positive control, we applied the selective KOP agonist U69,593 (1 µm), previously shown to inhibit dopamine release in the NAc (Di Chiara and Imperato, 1988a,b; Werling et al., 1988; Spanagel et al., 1992; Ebner et al., 2010; Karkhanis et al., 2016), at the end of each experiment, on top of N/OFQ since these drug responses were minimal. U69,593 caused a substantial decrease in stimulated dopamine release (electrical: 53 ± 5% of baseline (in N/OFQ), n = 15: linear mixed effects model, z = −8.9, p < 0.001; optical: 49 ± 3% of baseline (in N/OFQ), n = 17: linear mixed effects model, z = −13.9, p < 0.001; Fig. 7B). Therefore, the direct NOP modulation of this dopaminergic circuit occurs at a lower concentration and may be stronger in the somadendritic region where the terminals in the NAc are relatively insensitive to NOP activation. These results contrast with the KOP control of these neurons, which strongly inhibits release at the NAc dopamine terminals but does not directly hyperpolarize the cell bodies of these neurons (Margolis et al., 2006; Fig. 7C).
Discussion
The results presented here demonstrate that N/OFQ affects both dopaminergic and non-dopaminergic VTA neurons, through activation of the NOP, and in the majority of neurons causes inhibitory outward currents. N/OFQ effects in these neurons were blocked by the NOP-selective antagonist BTRX-246040, confirming its action at NOP. Importantly, neuronal responses to N/OFQ in VTA neurons desensitized at concentrations ≥100 nm. In addition to providing a basic characterization of the range of postsynaptic N/OFQ responses in VTA neurons, we demonstrated differential responding of subsets of VTA neurons to NOP activation related to projection target: mPFC-projecting and NAc-projecting VTA neurons responded to N/OFQ with outward currents (inhibitory), while most pACC-projecting VTA neurons responded with inward currents (excitatory). Within the dopaminergic projection to the NAc, although N/OFQ caused outward currents at the somatodendritic region of these neurons, release at the terminals was not inhibited by NOP activation. Together, these data show that N/OFQ effects in VTA neurons differ depending on their projection target and that at higher concentrations of N/OFQ only inhibitions are observed, followed by desensitization of NOP function.
Unexpectedly, a small population of neurons in the VTA, both TH(+) and TH(–), responded to low concentrations of N/OFQ with an inward current, consistent with excitation. This finding presents a novel mechanism by which N/OFQ could selectively activate specific VTA circuits, while inhibiting the majority of VTA outputs. Inward currents were observed in most VTA neurons projecting to the pACC, but not those projecting to the NAc or mPFC, consistent with this circuit-selection proposition. The fact that this effect was only observed at low concentrations indicates that very robust N/OFQ release into the VTA, on the other hand, would likely have a broad inhibitory effect on the vast majority of VTA neurons, regardless of circuit. Although NOPs are generally thought to couple to Gi/o and inhibit neural activity, some exceptions to this coupling have been reported for the related opioid receptors. Activation of postsynaptic MOP or DOP results in a Cav2.1 channel-dependent depolarization in subsets of VTA neurons (Margolis et al., 2014, 2017). Further, the MOP agonist DAMGO increases Cav2.1 currents in cerebellar Purkinje neurons (Iegorova et al., 2010) and morphine activates adenylyl cyclase in the corpus striatum and olfactory bulb (Puri et al., 1975; Onali and Olianas, 1991). While this is the first report of N/OFQ-mediated excitations in an acute brain slice preparation, intracellular increases in Ca2+ have been observed in a cultured human neuroblastoma cell line in response to N/OFQ in the presence of the cholinergic agonist carbachol (Connor et al., 1996). Therefore, while there are few reports of excitatory actions of N/OFQ, the observation is not unprecedented.
We also found that NOP activation signals through the canonical GIRK pathway in the SNc; however, in the VTA, N/OFQ outward currents were mediated by augmentation of GABAAR currents. This action via GABAARs is consistent with many of the N/OFQ-induced outward current sizes observed here being small, since our holding potential was only 10 mV depolarized from the calculated Cl– reversal potential. We note that while our population sampling was conducted in p22–p35 rats (Fig. 1), our mechanism experiments were conducted in adults, raising the possibility that there might be some differences in the populations of neurons. We have previously found similar electrophysiological properties and dopamine D2 receptor and KOP receptor pharmacological responses in VTA neurons recorded from p35 compared with adult (>p60) rats (Margolis et al., 2008), and others have also reported mature firing patterns, biophysical properties, and dopamine D2 receptor GIRK-mediated responses in SNc dopamine neurons early in postnatal development (Tepper et al., 1990; Walsh et al., 1991; Wang and Pitts, 1995). Since the range of N/OFQ responses in the control population is relatively large, small changes in the distribution of N/OFQ responses because of the blockers would be difficult to detect statistically. That said, among SNc recordings, a small sample size with more homogeneous N/OFQ responses was sufficient to demonstrate a GIRK contribution to N/OFQ responses in adult rats. Thus, while age differences are a noted caveat regarding the statistical comparisons made here, prior studies show other GPCR responses in these neurons appear mature in p22–p35 rats.
While both GIRK activation and the GABAAR dependent mechanism generated outward currents in our experimental preparation, the physiological consequences of these neural populations using different signaling pathways in vivo may vary. For instance, activating a GIRK will always cause a hyperpolarization, while increasing the GABAAR conductance will only occur when there is concurrent activation of NOPs and GABAARs. Further, the N/OFQ-induced neural inhibition requiring GABAAR activation depends on the Cl– reversal potential, which may be altered by a variety of behavioral states including pain, morphine treatment, stress, or alcohol exposure (Coull et al., 2003; Hewitt et al., 2009; Ferrini et al., 2013; Ostroumov et al., 2016; Santos et al., 2017). The N/OFQ response may even be excitatory in the absence of GABAAR activation, since blocking GABAARs seemed to increase the proportion of neurons in which we observed inward currents in response to N/OFQ (Fig. 5C).
In the VTA, neurons treated with a higher concentration of N/OFQ (≥100 nm) no longer responded to subsequent applications of N/OFQ in the VTA. This finding indicates that N/OFQ may act as a functional antagonist at the NOP by desensitizing these responses when higher concentrations of N/OFQ are present. Interestingly, we did not observe significant NOP desensitization in SNc neurons. NOP function is therefore apparently different from postsynaptic responses to agonists at the MOP and DOP in VTA neurons, where repeated application of saturating concentrations of selective agonists generate responses of similar magnitudes (Margolis et al., 2014, 2017). The apparent NOP desensitization we observed in the VTA is consistent with previous studies showing that high concentrations or repeated sustained exposure to NOP agonists causes desensitization in cell culture (Connor et al., 1996; Mandyam et al., 2000, 2002; Thakker and Standifer, 2002). In addition, NOPs internalize fairly rapidly (Spampinato et al., 2001, 2002; Corbani et al., 2004; Zhang et al., 2012) at the same concentrations that we observed desensitization. In vivo, N/OFQ administration can result in dose-dependent performance changes in behavioral spatial memory, locomotor, and anxiety tasks, with low-concentration N/OFQ having opposite effects compared with high doses (Florin et al., 1996; Jenck et al., 1997; Sandin et al., 2004). One possible explanation for these opposing behavioral outcomes is that N/OFQ may be acting as an agonist at low concentrations and a functional antagonist at high concentrations in some brain regions. An alternative possibility is that brain regions like the SNc that have less desensitization drive behavioral responses to high doses of N/OFQ, where brain regions like the VTA that show more desensitization mostly contribute to behavioral responses to lower N/OFQ doses.
N/OFQ inhibited both dopamine and non-dopamine neurons in the VTA that project to the NAc. This finding is consistent with the observation that N/OFQ administered ICV or into the VTA results in a decrease in extracellular dopamine in the NAc (Murphy et al., 1996; Murphy and Maidment, 1999). A prominent proposal in the literature is that a decrease in NAc dopamine produces aversion (McCutcheon et al., 2012). Therefore, one would expect ICV injection of N/OFQ to be aversive. However, this manipulation generates no response in the place conditioning paradigm (Devine et al., 1996). On the other hand, optogenetic or chemogenetic stimulation of N/OFQ containing inputs to the VTA can be aversive and decrease reward seeking (Parker et al., 2019). One possible explanation for this lack of clear motivational effect is the combination of inhibition of both dopamine and non-dopamine neurons: dopamine and non-dopamine neurons originating in the VTA synapse onto different types of neurons in the NAc, therefore affecting behavior in different ways. For instance, VTA glutamate neurons synapse onto parvalbumin containing interneurons in the NAc and optogenetic activation of these NAc-projecting glutamate neurons is aversive (Qi et al., 2016). Activation of NAc-projecting VTA GABA neurons causes a pause in cholinergic interneuron activity (Brown et al., 2012). These neurons modulate associative learning but are insufficient to drive preference or aversion independently (Collins et al., 2019) and do not appear to contribute to the detection of aversive gustatory stimuli (Robble et al., 2020). N/OFQ inhibition of dopamine, GABA, and glutamate neurons projecting to the NAc, therefore, may result in no net hedonic value and a lack of preference in a place preference paradigm. Further, various reports indicate that decreasing activity at dopamine receptors in the NAc via microinjections of antagonists does not produce aversion (Josselyn and Beninger, 1993; Baker et al., 1996, 1998; Morutto and Phillips, 1998; Laviolette and van der Kooy, 2003; Fenu et al., 2006; Spina et al., 2006; but see Shippenberg et al., 1991), and aversive outcomes can even be observed following manipulations that increase dopamine levels in the NAc (Devine et al., 1993b; Shippenberg and Bals-Kubik, 1995). Add to this the N/OFQ effects on other circuits following ICV injection, including other VTA neurons, and the possibility that the most robust, long-lasting effect is receptor desensitization at higher doses of agonist, together make it potentially less surprising that ICV N/OFQ was not reported to generate aversion.
N/OFQ’s effect on the VTA to NAc circuit provides an interesting point of comparison for how the NOP may be functionally distinct from the structurally related KOP. In vivo, systemic or ICV administration of N/OFQ or a KOP agonist each causes a decrease in extracellular dopamine in the NAc (Di Chiara and Imperato, 1988a,b; Devine et al., 1993a; Murphy et al., 1996; Murphy and Maidment, 1999). However, these two receptors function very differently in the dopamine neurons that project to the NAc. We show here that N/OFQ inhibits VTA cell bodies that project to the NAc but has little effect on the dopamine terminals within the NAc. KOP activation, on the other hand, has no effect on the cell bodies of NAc-projecting VTA dopamine neurons, but strongly inhibits dopamine release at the terminals in the NAc (Margolis et al., 2006; Britt and McGehee, 2008; Fig. 5C). One implication for this organization is that whether or not the respective endogenous peptides, N/OFQ and dynorphin, affect NAc-projecting dopamine neurons will depend on the brain region of peptide release. There is also evidence for dopamine release in the NAc that is independent of action potential firing in midbrain dopamine neurons (Cachope et al., 2012; Mohebi et al., 2019). In this organization of differential receptor effects localized to somadendritic regions versus terminals, dynorphin has control over this terminal activity while N/OFQ does not. Together, these observations bring into focus the critical importance of understanding precisely where receptors are functional in brain circuits and their specific actions at each site.
We found opposing effects of N/OFQ on the VTA projections to mPFC and pACC, which may contribute to the reported N/OFQ impact on behavioral measures associated with cortical dopamine function such as working memory, learning, and behavioral flexibility (Tzschentke, 2001; Winter et al., 2009; Gonzalez et al., 2014; Puig et al., 2014; Huang et al., 2019; Ott and Nieder, 2019). Our results also show that the non-dopamine VTA projections to cortical regions are affected by N/OFQ as well; while the majority of the VTA neurons that project to these cortical regions are not dopaminergic (Breton et al., 2019), little is currently known regarding their contribution to behavior. Preclinical studies show that ICV administration of N/OFQ impairs working memory (Hiramatsu and Inoue, 1999) and associative learning and memory (Goeldner et al., 2009), while blocking NOP with an antagonist or genetic knock-out enhances both working memory and learning (Noda et al., 1999; Jinsmaa et al., 2000; Nagai et al., 2007). How such a break on learning and memory by endogenous N/OFQ contributes to normal behavioral adaptation, and whether dopamine or other VTA outputs play a role, remains to be determined. One provocative possibility is that it is this degradation of working memory function that is the primary mechanism underlying the lack of place conditioning in response to central N/OFQ, rather than that this treatment is affectively neutral. This interpretation is consistent with work showing that N/OFQ blocks opioid induced conditioned place preference yet has no effect on opioid self-administration (Walker et al., 1998; Sakoori and Murphy, 2004).
The results of this study extend our understanding of the NOP system’s biology and provide considerations for additional investigation into NOP function within limbic circuits. These findings clarify that strong NOP desensitization occurs in neurons at moderate concentrations of the endogenous agonist N/OFQ. Importantly, not only does the nature of the NOP response vary with the projection target of VTA neurons, but the NOP function is largely sequestered to the somatodendritic compartment of VTA dopamine neurons that project to the NAc, demonstrating two different kinds of circuit level organization of this receptor system. Building on this groundwork, future studies of these VTA circuits during different behavioral states and tasks related to motivation and cognition will help to elucidate the differences between the normal and dysfunctional NOP-N/OFQ system, improving the potential for therapeutic targeting.
Acknowledgments
Acknowledgements: We thank Benjamin J. Snyder and Venkateswaran Ganesh for their technical assistance; Dr. Jing Cheng from the University of California, San Francisco Clinical and Translational Science Institute’s Biostatistics Consultation service for feedback on the statistical methods; and Howard L. Fields for helpful comments on this manuscript.
Footnotes
T.L.W. and W.J.M. are employees of and shareholders in BlackThorn Therapeutics, which is evaluating BTRX-246040 for the treatment of neurobehavioral disorders. All other authors declare no competing financial interests.
This work was supported by a sponsored research agreement from BlackThorn Therapeutics, Inc. to the University of California, San Francisco and the Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse Grant R01 DA042025.
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.